Valuation: Gilead Sciences, Inc.

Market Cap 18TCr 16TCr 15TCr 13TCr 25TCr 17,33600Cr 25TCr 1,71400Cr 67TCr 8,70300Cr 68TCr 67TCr 28,78300Cr P/E 2026 *
-44.6x
P/E 2027 * 18.2x
Enterprise Value 20TCr 17TCr 16TCr 15TCr 27TCr 18,93900Cr 28TCr 1,87300Cr 73TCr 9,50700Cr 74TCr 73TCr 31,44300Cr EV / Sales 2026 *
6.45x
EV / Sales 2027 * 5.82x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.32%
1 day+1.97%
1 week+5.84%
Current month+12.18%
1 month+9.48%
3 months+11.38%
6 months-4.37%
Current year+16.88%
1 week 28.07
Extreme 28.07
30.01
1 month 25.84
Extreme 25.84
30.01
Current year 23.97
Extreme 23.97
31.8
1 year 22.49
Extreme 22.49
31.8
3 years 20.08
Extreme 20.08
31.8
5 years 20.08
Extreme 20.08
31.8
10 years 20.08
Extreme 20.08
31.8
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+5.84% - - 18TCr
+0.88%+3.84%+77.96%+129.75% 1,10900Cr
+1.07%+3.11%+51.11%+56.67% 64TCr
+1.20%+5.64%+26.68%+76.48% 46TCr
+1.02%+3.67%+43.14%+47.27% 37TCr
+0.85%+2.97%+24.48%+42.54% 30TCr
+1.26%+4.54%+2.20%+14.84% 26TCr
+1.88%+5.14%+48.20%+67.80% 23TCr
+1.59%+0.87%-12.95%-51.91% 20TCr
+1.87%+5.78%+23.07%+92.57% 18TCr
Average +1.19%+3.00%+31.54%+52.89% 41.79TCr
Weighted average by Cap. +0.80%+3.26%+44.79%+72.24%

Financials

2026 *2027 *
Net sales 3.07TCr 2.63TCr 2.46TCr 2.25TCr 4.22TCr 2,93700Cr 4.28TCr 29TCr 11TCr 1,47400Cr 12TCr 11TCr 4,87600Cr 3.27TCr 2.8TCr 2.62TCr 2.4TCr 4.5TCr 3,12800Cr 4.56TCr 31TCr 12TCr 1,57100Cr 12TCr 12TCr 5,19400Cr
Net income -427.47Cr -366.05Cr -342.34Cr -313.39Cr -588.33Cr -41TCr -596.28Cr -4.04TCr -1.58TCr -21TCr -1.6TCr -1.57TCr -68TCr 1.03TCr 879.86Cr 822.86Cr 753.29Cr 1.41TCr 98TCr 1.43TCr 9.72TCr 3.79TCr 49TCr 3.86TCr 3.77TCr 1,63200Cr
Net Debt 1.67TCr 1.43TCr 1.34TCr 1.23TCr 2.3TCr 1,60200Cr 2.34TCr 16TCr 6.18TCr 80TCr 6.29TCr 6.15TCr 2,66000Cr 912.45Cr 781.34Cr 730.73Cr 668.95Cr 1.26TCr 87TCr 1.27TCr 8.63TCr 3.37TCr 44TCr 3.43TCr 3.35TCr 1,45000Cr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
21/26/21 CA$29.56 +1.97% 2,030
20/26/20 CA$28.99 -3.30% 2,248
19/26/19 CA$29.98 +3.70% 1,313
18/26/18 CA$28.91 +2.99% 693
17/26/17 CA$28.07 +0.43% 386
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
146.12USD
Average target price
157.41USD
Spread / Average Target
+7.72%

Quarterly revenue - Rate of surprise